Compare Adaptive Biotechnologies Corp (ADPT) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Orion Office REIT Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while Orion Office REIT Inc trades at $2.79 (market cap $157.99M). The key difference: Adaptive Biotechnologies Corp is far larger — about 21.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.88% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ONL | |
|---|---|---|
Market Cap | $3.33B | $157.99M |
Sector | Health | Real Estate |
52-Week High | $22.37 | $3.04 |
52-Week Low | $10.24 | $1.93 |
Enterprise Value | $3.19B | $641.64M |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ONL trades at $2.78, down 1.77% on the day, with a neutral technical signal and bearish moving averages. The company shows a gross margin of 56.71% but deep net losses, with revenue declining from $208M in 2022 to $148M in 2025. Recent news highlights progress on leasing and strategic reviews, while cash flow remains positive but shrinking.
Outlook is cautious due to persistent losses and high debt, though strategic asset sales and refinancing reduce near-term risks. The 50% analyst buy rating offers some optimism, but investors face significant fundamental challenges amid the troubled office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
